Winning! Mylan And Perrigo: Why Everybody Wins
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Mylan Beefs Up Topical Derm Business With Renaissance Buy
After a failed bid for Perrigo, Mylan continues to add to its portfolio with smaller deals that has it competing more closely with the former acquisition target.
Papa's Exit Highlights Perrigo's Shortcomings
After Papa's exit from Perrigo, the company is left to pick up the pieces and is not as strong a business as investors had previously thought.
Perrigo's Papa: Bridge Over Valeant's Troubled Waters Or Shark Bait?
Valeant Pharmaceuticals International Inc. hired Perrigo Co. PLC's Chairman and Chief Executive Joseph Papa to replace CEO Michael Pearson, but will Papa bridge the gaps between Valeant and its shareholders, debtors and the politicians who are demanding information about the company's drug pricing policies? Or, like Pearson, will he be bitten by the sharks in Valeant's troubled waters?